Per- and polyfluoroalkyl substances, known as PFAS, are a broad class of over 12,000 substances that are found in a variety of consumer, commercial and industrial products, including medical devices and their packaging. PFAS can essentially be divided into two separate classes: water soluble PFAS and water insoluble PFAS.
Learn more about PFAS in medical technology in our briefing document found on this page and in the video below.
Related Reading
Resource / Regulatory Affairs
Successful Market Access of SaMD & MDSW: Decoding the Confusion in MedTech Software Development
April 12, 2024
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.
News / Ethylene Oxide / Regulatory Affairs
AdvaMed Anticipates EtO Sterilization Rule, Voices Concern About Impact on Patient Care
February 27, 2024
By Friday, March 1, the Environmental Protection Agency is expected to finalize its regulation for the ethylene oxide (EtO) sterilization of 20 billion, or half, of all medical devices in the United States each year. AdvaMed President and CEO Scott Whitaker released the following statement:
Resource / Regulatory Affairs
Artificial Intelligence in Medtech
February 21, 2024
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.
Resource / Regulatory Affairs
Artificial Intelligence in Medical Technology Myths and Facts
February 21, 2024
Outlining the facts and dispelling myths will inform policymaking to avoid overlap with current regulations and preserve the broad capacity of innovation to help patients.
Resource / Regulatory Affairs
Principles for Artificial Intelligence in Medical Technology
February 21, 2024
This document provides the medical device industry’s foundational principles for artificial intelligence in medical technology. These principles will guide further innovations, policymaking, and regulations in AI-enabled medical technology.
Resource / Digital Health / Regulatory Affairs
AdvaMed Medical Device Cybersecurity Foundational Principles
February 8, 2024
Medical device manufacturers take seriously the need to continuously assess the security of their devices.
News / Medical Imaging / Regulatory Affairs
AdvaMed Urges FTC to Not Implement Right to Repair Policies for Medical Devices
February 8, 2024
Advamed, the Medtech Association, submitted comments to the Federal Trade Commission in response to a request for public comment on rulemaking regarding “right to repair” policies. AdvaMed and AdvaMed’s Medical Imaging division, in comments, outlined concerns regarding the impact of these policies as they relate to medical devices regulated by FDA.
Event / Digital Health / Government & Legislative Affairs / Regulatory Affairs
AdvaMed 2024 State Policy Briefing: AI in Healthcare
January 22, 2024
AdvaMed experts gave a presentation on how FDA regulates AI/ML in medical devices and how Medicare reimbursement policy is impacted by digital health technologies.